|
|
||||||||
1From the Center of Anatomy and Cell Biology, Integrative Morphology Group, and the 2Departments of Dermatology, 3Medicine I, Division Institute of Cancer Research, and 7Ophthalmology and Optometry, General Hospital, Medical University Vienna, Vienna, Austria; the 4Institute of Anatomy, Histology and Embryology, Department of Clinical and Functional Anatomy, Medical University of Innsbruck, Innsbruck, Austria; 5Transplantation Research, Novartis Pharma AG, Basel, Basel, Switzerland; and 6Novartis Pharma AG, Vienna, Vienna, Austria.
| Abstract |
|---|
|
|
|---|
METHODS. Eleven monkeys (Macaca fascicularis) of both sexes, between 4 and 6 years of age were analyzed. Whole EOM myotendons were immunostained with four combinations of triple-fluorescent labeling and examined by confocal laser scanning microscopy. Labeling included antibodies against choline acetyltransferase (ChAT), vesicular acetylcholine transporter (VAChT), neurofilament, and synaptophysin. Muscle fibers were counterstained with phalloidin.
RESULTS. Palisade endings were observed in all monkey EOMs. Nerve fibers extended from the muscle into the tendon and looped back to divide into a terminal arborization (palisade ending) around a single muscle fiber tip. In approximately 30% of the cases, nerve fibers supplying palisade endings often established motor terminals outside the palisade complex. Nerve fibers forming palisade endings were ChAT-neurofilament positive. Axonal branches of palisade endings were ChAT-neurofilament positive as well. All palisade nerve terminals exhibited ChAT-synaptophysin immunoreactivity. Within the palisade complex, palisade nerve terminals exhibited VAChT immunoreactivity. All palisade nerve terminals were VAChT-synaptophysin immunoreactive.
CONCLUSIONS. The results confirm that in the monkey, palisade endings contain acetylcholine and are therefore most likely effector organs. Palisade endings are also present in human EOMs and because of their location at the myotendinous junction, these organs are of crucial interest for strabismus surgery.
Dogiel4 was one of the first scientists who described palisade endings (innervated myotendinous cylinders) in the EOMs of several mammals and humans. The observations of Dogiel were confirmed later in monkeys,5 cats,6 7 8 and humans.9 10 Palisade endings were also detected and confirmed in rabbit EOMs11 12 and have been described recently in EOMs of sheep,13 and rats.14
Palisade endings are encapsulated nerve end organs unique to EOMs of mammals. They are located at the myotendinous junction and consist of a dense ramification of preterminal axons and their vesicle-laden nerve terminals around a single muscle fiber tip. Most palisade nerve terminals have established contacts to the tendon and only a few of them have contacts to the muscle fiber surface. Palisade endings in rabbits and rats are an exception, since exclusively neuromuscular contacts have been observed.11 14 Palisade endings arise from nerve fibers that, coming from the muscle, extend into the tendon and then turn back 180° to terminate around a single muscle fiber tip. Each palisade ending is associated with a multiply innervated muscle fiber that has several motor contacts along its length.
Although physiological evidence is missing, there is a consensus that palisade endings are sensory organs,1 2 5 6 7 14 15 and Spencer and Porter16 have concluded that palisade endings potentially represent the principal proprioceptor type for mammalian EOMs. Nevertheless, in a few publications, a motor role11 17 or a sensorymotor role9 of this EOM specific organ is favored.
In our latest study,8 we analyzed palisade endings in cat EOMs by using antibodies against choline acetyltransferase (ChAT). The antibodies against ChAT label cholinergic nerve fibers in the central and peripheral nervous system.18 19 20 We showed that the nerve fibers supplying palisade endings and the palisade complexes themselves were ChAT positive. In a few palisade endings, we observed neuromuscular contacts that were
-bungarotoxin positive as well. Morphologically, we detected several times that the same nerve fiber supplying palisade endings established motor contacts outside the palisade complex. In summary, the results of our previous study provided evidence that palisade endings exhibit molecular and morphologic characteristics of effector organs.8
It was the purpose of the present study to examine our surprising finding that palisade endings are putative effector organs in a primate species that is evolutionary closely related to humans. In addition to antibody against ChAT we used antibody against vesicular acetylcholine transporter (VAChT) to analyze palisade endings. VAChT is a vesicle membrane protein and is responsible for the uptake of acetylcholine into synaptic vesicles. VAChT is used to identify cholinergic nerve terminals in the central and peripheral nervous system.18 19
| Materials and Methods |
|---|
|
|
|---|
Eleven monkeys (Macaca fascicularis), eight females and three males aged between 4 and 6 years and weighing between 2.4 and 3.8 kg, were analyzed in the study. The eyeballs, including the distal parts of the EOMs were obtained from Novartis Pharma AG (Basel, Switzerland). The distal parts of the four rectus EOMs and two oblique EOMs, including the tendons, were removed. Tissue was immersion fixed with 4% paraformaldehyde in 0.1 M phosphate buffer (PB; pH 7.4) for 24 hours and then rinsed in 0.1 M phosphate-buffered saline (PBS; pH 7.4). The EOMs were further processed for confocal laser scanning microscopy.
Confocal Laser Scanning Microscopy
A total of 132 EOMs were analyzed. Distal EOM myotendons were divided into four groups, each group containing 33 EOMs, both rectus and oblique. Different combinations of triple fluorescent labeling were applied to the whole specimens. These wholemounts were labeled with: (1) phalloidin and antibodies against ChAT and neurofilament; (2) Phalloidin and antibodies against ChAT and synaptophysin; (3) phalloidin and antibodies against VAChT and neurofilament; and (4) phalloidin and antibodies against VAChT and synaptophysin.
Procedure for Triple-Fluorescent Labeling
A detailed description of the staining protocol of EOM wholemounts is given by Konakci et al.8 Herein, we provide a condensed version. The marker for muscle fibers, the primary antibodies, and secondary antibodies, and the working dilutions and the sources, are listed in Table 1 .
|
Wholemounts were examined under a confocal laser scanning microscope (CLSM; model LSM 410; Carl Zeiss Meditec, Oberkochen, Germany). When palisade endings were identified, series of longitudinal virtual CLSM sections of 0.4- to 1-µm thickness were cut through the specimens. Each section was photodocumented, and three-dimensional projections were formulated on computer (LSM Image Examiner software; Carl Zeiss Meditec).
Control Experiments
In negative control experiments, the primary antibodies were omitted and the secondary antibodies were used alone. In all cases, the omission of the primary antibodies resulted in a complete lack of immunostaining.
Positive control experiments were performed on cryostat sections of monkey EOMs. Sections were double labeled with anti-ChAT and
-bungarotoxin or alternatively with anti-VAChT and
-bungarotoxin. Muscle fibers were counterstained with phalloidin. In both experiments
-bungarotoxin-positive motor endplates were also positive for ChAT and VAChT.
| Results |
|---|
|
|
|---|
-bungarotoxin and immunoreactive for ChAT and VAChT as well (Fig. 1) . The nerve fibers supplying motor terminals were ChAT immunoreactive (Fig. 1A) .
|
Palisade endings were supplied by thin nerve fibers (23 µm in diameter) which came from the muscle and extended into the tendon. Within the tendon, the nerve fibers curved back to divide into a terminal arborization around single muscle fiber tips (Figs. 2 3 4) . In several cases, the nerve fibers reached the palisade complex at the muscle fiber tip more directly without previously turning back from the tendon (Fig. 3C) .
|
|
|
Palisade endings consisted of axonal branches that formed nerve terminals that lay within the tendon and around the muscle fiber surface (Figs. 2 3 4 5) . Other palisade nerve terminals lay between the muscle fiber processes that attached the muscle fiber to the tendon (Fig. 3A , inset). In some palisade endings, we observed nerve terminals exclusively in the tendon compartment (Figs. 2B 3B 5B) .
|
Labeling with Phalloidin and Antibodies against ChAT and Neurofilament
All nerve fibers forming palisade endings were positive for neurofilament as well as for ChAT (Fig. 2) . We never found a palisade complex that originated from a neurofilament-positive but ChAT-negative nerve fiber. We also did not detect palisade endings that had dual innervationnamely, by a nerve fibers being positive for ChAT-neurofilament and by another nerve fibers being only neurofilament positive.
The axonal branches of the palisade endings were also neurofilament-ChAT immunoreactive. Axonal branches of palisade endings, being only positive for neurofilament were never observed (Fig. 2) .
Labeling with Phalloidin and Antibodies against ChAT and Synaptophysin
We observed ChAT-positive nerve fibers that split into palisade endings at the myotendinous junction. The axonal branches of the palisade endings were also ChAT immunoreactive. All palisade nerve terminals were immunoreactive for synaptophysin and for ChAT (Fig. 3) . Nerve terminals that stained solely synaptophysin positive were never observed.
Labeling with Phalloidin and Antibodies against VAChT and Neurofilament
Neurofilament-positive nerve fibers coming from the muscle penetrated the tendon and then looped back to supply palisade endings on muscle fiber tips. The axonal branches of the palisade endings established nerve terminals that exhibited VAChT immunoreactivity (Fig. 4) .
Labeling with Phalloidin and Antibodies against VAChT and Synaptophysin
By using this combination of triple labeling, we stained the muscle fibers and the palisade nerve terminals. The nerve fibers supplying the palisade endings and the axonal branches of the palisade endings were not labeled. The region of thepalisade endings, the EOM tendon junction, was easy to identify because there the phalloidin-labeled muscle fibers were attached to the unstained tendon. All palisade nerve terminals exhibited immunoreactivity for synaptophysin and VAChT (Fig. 5) . We detected no nerve terminals that were only synaptophysin positive.
| Discussion |
|---|
|
|
|---|
Consistent with our morphologic findings in cat,8 we observed in monkey that nerve fibers supplying palisade endings often establish motor terminals outside the palisade complex. In monkey, approximately 30% of the palisade endings exhibit such an additional motor innervation from the same nerve fiber. As in the cat,8 we showed in the monkey that palisade endings arise from nerve fibers that contain ChAT. Axonal branches of palisade endings and palisade nerve terminals contain ChAT as well. Moreover, in this study we demonstrated for the first time that palisade nerve terminals contain the VAChT protein. The VAChT immunoreactivity of palisade nerve terminals correlates well with morphologic findings in palisade endings. In particular, fine structural investigations of palisade endings in monkey,5 cat,6 8 sheep,13 and humans9 demonstrate that palisade nerve terminals, both at the tendon and at the muscle fiber, exhibit dense aggregations of clear vesicles. VAChT is a vesicle membrane protein and anti-VAChT is a marker for synaptic vesicles.18 19 The VAChT immunoreactivity of palisade nerve terminals strongly suggests that the VAChT protein is a membrane constituent of the vesicles in palisade nerve terminals.
This is the first report that demonstrated a ChAT-VAChT immunoreactivity of palisade endings. ChAT is the synthesizing enzyme for the neurotransmitter acetylcholine and VAChT is a necessary requisite to transport acetylcholine into synaptic vesicles of axonal terminals. Thus, the present study in monkey definitively proves that palisade endings synthesize acetylcholine, which is stored in the vesicles of palisade nerve terminals. Because acetylcholine is the classic neurotransmitter of nerve terminals that in other locations are universally motor, we conclude that palisade endings may act as effectors organs. We confirmed the putative effector role of palisade endings in monkey, a primate species that is evolutionary close to humans. It is therefore tempting to speculate that palisade endings in human EOMs may also fulfill an effector function.
Recent studies have shown that multiple neurotransmitters (glutamate21 ) and neuromodulatory agents (CGRP22 and substance P23 ) are found in nerve terminals. It would be a challenge to conduct future studies to examine whether palisade endings contain other neurotransmittersneuromodulatory agents beside acetylcholine.
Until now, physiological studies on palisade endings are lacking. The major arguments to classify palisade endings as proprioceptors came from fine structural investigations5 6 13 and a neuronal tracing experiment.7 In fine structural studies of rhesus monkey,5 cat,6 and sheep,13 palisade nerve terminals contacting the collagen fibrils as target structures were arguably considered to be sensory. Palisade nerve terminals contacting the muscle fiber lack a basal lamina in the synaptic cleft that is analogous to sensory neuromuscular contacts in muscle spindles. After injecting neuronal tracers into the trigeminal ganglion that is supposed to harbor the perikarya of the nerve fibers innervating EOM proprioceptors, Billig et al.7 described three kinds of labeled nerve endings in cat EOMsone type resembling palisade endings.
Morphologically, we observed in the monkey that nerve fibers supplying palisade endings establish motor terminals outside the palisade complex. Immunohistochemically, we confirmed that palisade endings are cholinergic structures. In particular, labeling monkey EOMs with a cholinergic marker (anti-ChAT) and a general marker for nerve fibers (anti-neurofilament) demonstrated that palisade endings are exclusively supplied with cholinergic nerve fibers. All axonal branches of palisade endings are cholinergic as well. Noncholinergic nerve fibers were never found to form palisade endings. Further, a dual innervation of the palisade complex with cholinergic and noncholinergic nerve fibers was also never observed. In the same line, labeling EOMs with antibody against ChAT and a general marker for nerve terminals (anti-synaptophysin) showed that all nerve terminals of the palisade complexes are cholinergic. Labeling monkey EOMs with another cholinergic marker (anti-VAChT) confirmed the cholinergic phenotype of palisade nerve terminals. Immunostaining with antibodies against VAChT-synaptophysin revealed that all palisade nerve terminals are cholinergic. In summary, morphologic findings and immunoreactivity for cholinergic markers strongly favor an effector role of palisade endings.
Recently, Tata et al.24 detected that small and medium-sized sensory neurons in the dorsal root ganglion of rats are VAChT immunoreactive. Based on these findings, one might speculate that palisade endings are cholinergic sensory structures. Terminals on the muscle fiber from the same nerve fiber supplying a palisade ending would have to be interpreted as either sensory as well, or the nerve fiber would have to serve a dual (sensory and motor) cholinergic function. In the present study, we provided evidence that palisade endings exhibit ChATVAChT immunoreactivity which is identical with classic motor terminals. Further, we showed that palisade endings arise from nerve fibers establishing motor terminals outside the palisade complex. We conclude that these findings are strong arguments in support of our assumption that palisade endings are effectors.
Supporting evidence that palisade endings are putative effector organs comes from degeneration experiments17 and
-bungarotoxin labeling.8 11 After stereotactic lesions of the abducens, trochlear, and occulomotor nuclei in cats, Sas and Scháb17 found that besides motor nerve terminals, all palisade endings were degenerated in the EOMs. In cat, palisade nerve terminals contacting the muscle fiber were observed in few palisade endings.8 Such neuromuscular contacts stained positively for
-bungarotoxin.8 In palisade endings of rabbit EOMs, neuromuscular contacts had a basal lamina in the synaptic cleft which is typical of motor terminals.11 Binding of
-bungarotoxin to neuromuscular contacts confirmed the motor role.11 It is important, however, to note that palisade endings in rabbit EOMs are different, since neurotendinous contacts that are a regular feature in palisade endings of all other species, including humans, are absent.
In humans, the hypothesis was put forward that palisade endings may combine motor and sensory functions. Lukas et al.9 found sensorylike neurotendinous contacts and motor neuromuscular contacts in palisade endings of human EOMs. Motor neuromuscular contacts were endowed with a basal lamina in the synaptic cleft and bound
-bungarotoxin. In the cat8 and now confirmed in the monkey, we showed that exclusively cholinergic nerve fibers form palisade endings that are endowed exclusively with cholinergic nerve terminals. These findings suggest a motor innervation of this EOM-specific organ.
Functional Considerations
The functional significance of palisade endings with a putative effector role is difficult to predict. In palisade endings, most nerve terminals are at the tendon and are in intimate contact with the surrounding collagen bundles. It is unclear what effect a release of neurotransmitter (acetylcholine) might have on the neighboring collagen. Otherwise, neurotendinous contacts are at a great distance from the muscle fiber, and after acetylcholine release there is a long distance for the neurotransmitter to diffuse to a cholinergic receptor site on the muscle fiber surface. Nerve terminals being far away from their target would mean that palisade endings belong to a motor system that is different from the classic motor system in skeletal muscle, because there, motor terminals are always in close contact with the muscle fiber, and the neurotransmitter release site and receptor site reside close together.
The importance of afferent signals from EOM proprioceptors is demonstrated in several studies. In cats, it was shown that EOM proprioception plays a role in orienting behavior and in depth perception.25 26 In humans, several studies support the assumption that EOM proprioceptors provide information about the eye position in the orbit.27 28 29 30 In particular, in behavioral experiments, it has been shown that subjects in whom the afferent input from the EOMs has been either disrupted or altered, fail to localize targets in the surrounding space exactly. Such deficits were interpreted as a sign that subjects receive insufficient afferent signals about the eye position, which in turn led to misinterpretation in the spatial localization of visual targets.27 28 29 30
The endowment with classic proprioceptors (Golgi tendon organs and muscle spindles) in mammalian EOMs shows striking interspecies variations. Muscle spindles and Golgi tendon organs are numerous in even toed ungulates,31 32 33 34 35 but only a few muscle spindles and one to two Golgi tendon organs were observed in the EOMs of rhesus monkey.1 36 Human EOMs contain muscle spindles, whereas Golgi tendon organs are reported to be absent.1 37 38 39 In EOMs of the cat, rabbit, guinea pig, and rat, neither muscle spindles nor Golgi tendon organs are found.3 Particularly in those EOMs in which muscle spindles and/or Golgi tendon organs are few or absent, palisade endings are considered to be an alternative sensory end organ.15 In this study, we confirmed in a primate species that palisade endings are putative effector organs and therefore these organs would not provide information about the eye position. Our findings that palisade endings may be effectors are not only of scientific interest but also have clinical relevance. Palisade endings are also present in human EOMs and are located at the myotendinous junction, the very target area of strabismus surgery.
| Acknowledgements |
|---|
| Footnotes |
|---|
Submitted for publication June 9, 2005; revised August 2, 2005; accepted September 28, 2005.
Disclosure: K.Z. Konakci, None; J. Streicher, None; W. Hoetzenecker, None; I. Haberl, None; M.J.F. Blumer, None; G. Wieczorek, Novartis Pharma AG, Basel (E, F); J.G. Meingassner, Novartis Pharma AG, Vienna (E, F); S.L. Paal, None; D. Holzinger, None; J.-R. Lukas, None; R. Blumer, None
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C.
1734 solely to indicate this fact.
Corresponding author: Roland Blumer, Center of Anatomy and Cell Biology, Integrative Morphology Group, Medical University Vienna, Waehringerstrasse 13, 1090 Vienna, Austria; roland.blumer{at}meduniwien.ac.at.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
X. Shan, J. Tian, H. S. Ying, C. Quaia, L. M. Optican, M. F. Walker, R. J. Tamargo, and D. S. Zee Acute Superior Oblique Palsy in Monkeys: I. Changes in Static Eye Alignment Invest. Ophthalmol. Vis. Sci., June 1, 2007; 48(6): 2602 - 2611. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |